Login Signup Home Sitemap Contact us



Home > Research > Medicinal Chemistry
 
Alzheimer’s Disease (AD) is a major cause of dementia. It is believed to affect 11% of all humans over 65% of age and 50% over age of 85 in caucasian populations. Clinical symptoms of AD include confusion, poor judgments, language disturbances, agitation, and hallucinations. Death in AD occurs due to general inanition, malnutrition and pneumonia. The accumulation of Aβ plaques is now considered one of the most significant factors in AD. Aβ aggregate-specific probes for in vitro and in vivo studies of Aβ plaques are potentially important for diagnosis and monitoring of therapeutic effects of drugs aiming at lowering the Aβ burden in the brain by noninvasive imaging. The in vivo imaging of Aβ plaque may provide information to understand better AD symptoms vs Aβ burden in the brain. currently, small molecule based diagnostic imaging agents for Aβ aggregates in the brain can be labeled with a suitable isotope for PET or SPECT imaging.We are developing a new series of cold and hot fluorinated compounds to use as imaging agents for in vivo study of Aβ-42 plaques.